Five years of nationwide use of whole genome sequencing in ongoing pregnancies: Diagnostic yield, timing, and implementation
Variant / mechanism
Pathogenic or likely pathogenic variants identified by trio prenatal genome sequencing
Summary
This Danish nationwide cohort includes all singleton pregnancies that underwent prenatal genome sequencing after a normal chromosomal microarray between 2019 and 2023, across the country's four clinical genetics laboratories. Of 207 cases (85 chorionic villus samples and 122 amniotic fluid samples), sequencing was performed as a trio in 98.6%, ordered at a median gestational age of 20 weeks, with a median turnaround time of 11 working days. A pathogenic or likely pathogenic variant explaining the phenotype was found in 33 pregnancies (15.9%), with the highest yield in hydrops (25.0%) and multiple anomalies (24.3%), and the lowest in isolated increased nuchal translucency (7.1%). Secondary findings were reported in 18 cases (8.7%); the impact of results on parental decisions and pregnancy outcomes was not assessed.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
Five years of national experience show that trio prenatal genome sequencing fits within the timeframe of an ongoing pregnancy, with a yield after normal microarray ranging from 7% to 25% depending on the indication. Isolated increased nuchal translucency remains the least productive indication, which helps prioritise requests. The 8.7% rate of secondary findings must be anticipated in pre-test counselling.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime